FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 19 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma Aiming to support a robust regulatory ecosystem for driving cancer research in Europe, ESMO provides feedback to the public consultation on dataset descriptions under... MOST POPULAR Does Sugar Feed Cancer? March 19, 2021 How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective June 28, 2022 COVID-19 vaccine and cancer – latest updates November 20, 2020 Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... February 3, 2020 Load more HOT NEWS Transforming optimism: finding new ways to treat rare cancers Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval When Prenatal DNA Tests Point to Cancer ‘Will cancer make me infertile?’ – That Cancer Conversation
